Licensing & Agreements
Our goal is to get our technology out to where it is needed quickly, reducing as many hurdles to licensing as we possibly can.
If you would like to use one of our technologies or software platforms, please reach out to us so we can help get this facilitated.
Research FAQs
- Human Subjects/Clinical Research- On Monday, March 16, the Duke School of Medicine Clinical Research Administration initiated the Essential Clinical Research Study Policy. At that time, all in-person clinical research study activities for Tier 3, non-essential, studies were temporarily suspended until further notice. While other clinical research activities that can be done virtually or remotely are able to continue, participant in-person visits are not allowed.
- For studies in the Campus Institutional Review Board (IRB)
Federal Guidance FAQs
FAQs that address federal “policy” questions (as distinct from legislative/funding questions) that the COVID-19 pandemic raises for research universities.